Parkinson’s Disease – Challenges in New Drug Development by Tomislav Babić & Darija Mahović
Coll. Antropol. 32 (2008) 4: 1275–1281
Professional paper
Parkinson’s Disease – Challenges in New Drug
Development
Tomislav Babi}1 and Darija Mahovi}2
1 CNS International, I3 Research, Maidenhead, Berks, UK
2 Department of Neurology, University Hospital Center »Zagreb«, Zagreb, Croatia
A B S T R A C T
Idiopathic Parkinson’s disease (IPD) is the second most common neurodegenerative disorder after Alzheimer’s dis-
ease. Treatment aims in IPD include the provision of symptomatic relief, reduction of functional disability, halting or
slowing of the neurodegenerative process, and the prevention of long-term complications by proper initiation of therapy.
At present, pharmacotherapeutic strategies allow the amelioration of motor symptoms of IPD only, whereas non-motor
manifestations are not helped by dopamine replacement strategies. In addition, levodopa-induced fluctuation and dy-
skinesia are still challenging, particularly in long-term treatment. Despite advances in pharmacotherapy that have im-
proved quality of life for these patients, the mortality rate remains largely unchanged. Sustained interest in IPD will
hopefully allow increased funding of research to develop new and better treatments.
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Introduction
Idiopathic Parkinson’s disease (IPD) is the second
most common neurodegenerative disorder after Alzhei-
mer’s disease, with over 100,000 patients diagnosed in
the United Kingdom and at least 8,000 new cases diag-
nosed annually. In the United States, approximately 1%
of those over 65 and 3% of those over 85 years of age are
diagnosed with IPD1. Prevalence and incidence will con-
tinue to increase with the aging population. IPD is char-
acterized pathologically by the loss of pigmented dopami-
nergic neurons associated with eosinophilic cytoplasmatic
inclusions (Lewy body) mainly in the substantia nigra
and locus ceruleus. This neuronal loss results in a signifi-
cant decrease of dopamine levels in the brain; patients
become symptomatic when this decrease is over a certain
threshold. The course of the clinical decline parallels that
of the progressive degeneration of the remaining dopa-
minergic neurons2.
Although IPD is relatively common, it can be difficult
to diagnose clinically, particularly in early stages. Ap-
proximately 5 to 10% of patients with IPD are misdia-
gnosed3. Conversely, up to 20% of patients diagnosed
with IPD reveal alternative diagnoses at autopsy, such as
multiple system atrophy (MSA), progressive supranu-
clear palsy (PSP), corticobasal degeneration (CBD), Alz-
heimer’s disease type pathology, and cerebrovascular di-
sease4–7. Diagnostic criteria such as the UK PD Society
Brain Bank criteria3 have been developed; however, it
has been suggested that an accuracy of 90% is the best
that can be achieved with clinical assessment and clinical
diagnostic criteria5.
Clinical Presentation
The UK PD Society Brain Bank criteria allows for dif-
ferentiation between IPD and parkinsonism. The term
parkinsonism refers to a clinical syndrome comprising
combinations of motor symptoms and signs: bradyki-
nesia (slowness and decreased amplitude of movement),
tremor-at-rest, muscle rigidity, loss of postural reflexes,
flexed posture, and the freezing phenomenon (where the
feet are transiently »glued« to the ground). At least two
of these six cardinal features need to be present before
the diagnosis of parkinsonism is made, with at least one
of them being tremor-at-rest or bradykinesia. Idiopathic
Parkinson disease is the major cause of parkinsonism
and can also be referred to as primary parkinsonism, in
contrast to the other three parkinsonian designations,
namely: 1) secondary, such as drug-induced parkinsonism,
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postencephalitic, vascular, mass-lesion induced, or toxic
parkinsonism; 2) Parkinson-plus syndromes (presence of
parkinsonism plus other neurological features) such as
progressive supranuclear palsy (PSP), multisystem atro-
phy (MSA), corticobasal degeneration (CBD); and 3) he-
rodegenerative disorders in which parkinsonism is only
one feature of a hereditary degenerative disorder, such as
juvenile Huntington’s disease and Wilson’s disease. Three
of the most helpful indicators of IPD that distinguish it
from another category of parkinsonism are: 1) an asym-
metrical onset of symptoms and signs (IPD often begins
on one side of the body), 2) the presence of resting tremor
(although resting tremor may be absent in patients with
IPD – it is almost always absent in Parkinson plus syn-
dromes), and 3) substantial clinical response to adequate
levodopa therapy (usually Parkinson-plus syndromes do
not respond to levodopa therapy)8. IPD is a slowly pro-
gressive parkinsonian syndrome that begins insidiously,
gradually worsens in severity, and usually affects one
side of the body before spreading to involve the other
side. Resting tremor is often the first symptom recog-
nized by the patient, but the illness sometimes begins
with bradykinesia. In some patients, tremor may never
develop. Symptoms steadily worsen over time, which, if
untreated, leads to disability with severe immobility and
increased risk of falling. The early symptoms and signs of
IPD (rest tremor, bradykinesia, and rigidity) are usually
correctable by treatment with levodopa or/and dopamine
(DA) agonists. As IPD progresses over time, symptoms
that respond poorly to levodopa or DA agonists develop,
such as flexed posture, the freezing phenomenon, and
loss of postural reflexes; these are often referred to as
non-DA-related features of PD. Moreover, bradykinesia
that responded to levodopa or DA agonists in the early
stage of IPD increases as the disease worsens and no lon-
ger fully responds to levodopa or DA agonists. It is partic-
ularly these intractable motor symptoms that lead to the
progressive disability. Disability associated with IPD in-
cludes not only motor dysfunction, but also many non-
-motor symptoms like dysautonomia (autonomic nervous
system dysfunction), fatigue, depression, anxiety, sleep
disturbances, constipation, bladder and other autonomic
disturbances (sexual, gastrointestinal), sensory compla-
ints, decreased motivation and apathy, slowness in think-
ing (bradyphrenia), and a declining cognition that can
progress to dementia.
Challenges of the Current Treatment
Strategy
Currently available therapies are most effective in
minimizing the motor dysfunction of IPD through in-
creasing the activity of the remaining intact neurons (not
affected, or only partially affected by degeneration) of the
nigrostriatal dopamine system. Nearly 70–80% of dopa-
minergic neurons have already degenerated when first
signs of disease have become evident2. Since only 20–30%
of remaining dopaminergic neurons are available to the
current pharmacological intervention and the degenera-
tive process continues, it is clear why the overall benefit
of treatment is partial and not sustained over the years
of disease. In the early stages of the disease, the brain
still retains sufficient dopaminergic reserves to buffer
the fluctuations in dopaminergic stimulation by the exo-
genous dopaminergic medications9; despite levodopa ha-
ving a short half-life (60 to 90 minutes)10, patients still
experience benefit despite missing a dose of medica-
tion11. As dopaminergic neurons continue to degenerate
in this progressive disease, the fluctuations manifest
clinically as the buffering capacity diminishes9 and the
striatum becomes dependent on the peripheral availabil-
ity of levodopa12. This leads to motor fluctuations, where
the patient alternates between »on« periods in which
levodopa provides benefit, and »off« periods when the
levodopa benefit »wears off« prior to the next dose with
worsening symptoms11. These unbuffered fluctuations in
the plasma concentration of short-acting levodopa may
impact directly on the striatum, with alternating high
and low levels of striatal dopamine exposed to dopamine
receptors. This pulsatile stimulation of the striatal dopa-
mine receptors is now thought to be a key factor in the
development of the levodopa-associated motor complica-
tions of IPD11 through induction of changes in striatal
neuronal plasticity, dysregulation of genes and proteins,
and alterations in neuronal firing patterns12. Observa-
tions that the half-life of dopaminergic agents and dis-
ease severity (i.e., degree of nigrostriatal cell loss) are im-
portant factors in the development of motor fluctuations
and dyskinesias13 are consistent with this hypothesis.
These motor complications can impair quality of life and
cause significant disability14. Risk factors for motor com-
plications include younger age at onset of IPD, disease
severity, higher levodopa dosage, and longer disease du-
ration and levodopa treatment15–16. Several types of mo-
tor fluctuations have been described, the most common
being the »wearing-off« effect. With this pattern, pa-
tients develop a predictable worsening of their parkinso-
nism at the end of their current dose and before their
next scheduled dose of levodopa. This leaves them in an
»off« state, in which clinical features such as tremor,
bradykinesia, and limb rigidity return. Off state symp-
toms can be disabling because they lead to immobility.
Some patients react to off states with panic attacks,
screaming, or even drenching sweats17. The predictabil-
ity of these off states enables the patients to clearly de-
scribe the average length of their »on« states and the du-
ration and number of off states during the day. A predict-
able wearing off effect might be expected in nearly 20%
of patients treated with levodopa within 5 years, 45%
treated within 9 years, and 100% of those treated more
than 10 years16. The pathophysiology of the wearing-off
effect is believed to relate to disease progression and the
pharmacokinetics of levodopa. As the disease progresses,
the duration of the on state progressively shortens, pre-
sumably owing to the reduced capacity for presynaptic
storage of dopamine by nigral neurons18. Due to levo-
dopa’s short half-life, the duration of the typical on state
progressively shortens as the disease progresses until the
on states may last no longer than 1 hour. With disease
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progression, there is a tendency for the fluctuations to
become increasingly less predictable. As the wearing off
becomes more complicated, dosing responses also vary
and patients may report a »delayedon« effect or dose fail-
ures (otherwise known as the »no-on« effect or the »ski-
pped-dose« effect). Delayed-on refers to a significant and
unusual delay between the taking of a dose of levodopa
and the commencement of its effects. No-on occurs when
a given dose of levodopa is not effective at all. When this
happens, the off state is dramatically prolonged, further
increasing disability. The timing of these events is often
unpredictable. In many patients, it seems that the major-
ity of the total daily off time is actually time spent wait-
ing for a dose of levodopa to take effect19. The on–off ef-
fect is the most unpredictable of fluctuating states. This
also produces off states, but in a seemingly random fash-
ion, such that patients cannot predict when the next off
state will occur. These episodes vary in time, are unre-
lated to medication doses, and occur suddenly. Patients
with the on-off effect usually have more advanced dis-
ease. This phenomenon is rarely seen within the first 5
years of levodopa treatment, but it is present in 50% of
those treated more than 10 years16. Most patients with
the on-off effect also experience the wearing off effect, so
that some off states may be predictable and others are
not. The unpredictability of off states significantly in-
creases disability and negatively affects patient quality of
life. The underlying cause of the on-off effect is poorly
understood. The pharmacokinetic and pharmacodyna-
mic proprieties of levodopa have been considered as pos-
sible explanation of this phenomenon, but it is still a
mystery why the effect occurs only in very advanced IPD.
In addition to levodopa-related periods of immobility,
many patients experience levodopa-induced dyskinesias.
Unlike the off phenomenon, dyskinesias usually accom-
pany the on state. The most common type of dyskinesia
is seen at the peak of the clinical effect of levodopa,
so-called »peak-dose« dyskinesias. It is rare within the
first 5 years of levodopa treatment (11%), but very com-
mon after 10 years of treatment (89%)16. These move-
ments (which are typically choreiform or dystonic) can be
mild and of no consequence, or severe enough to be dis-
abling. The chief importance of dyskinesias when the
treatment of off states is considered is the fact that most
medical strategies for reducing off states have increased
dyskinesias as a side effect. It is often necessary to strike
a balance between minimizing off time while not greatly
accentuating dyskinesias. Another form of dyskinesia is
diphasic dyskinesia, where choreic or dystonic move-
ments occur at the beginning or end of the levodopa dose
as the serum levels are changing. It appears to involve
legs more than the other types of dyskinesia, and it also
appears to be more troublesome than the peak-dose type.
Some patients have both types and therefore experience
dyskinesias during the entire on state. The current con-
cept of pharmacological treatment in early IPD is purely
symptomatic and directed to the motor symptoms only. It
should be considered for the patient who develops func-
tional disability, which varies with the individual. Pa-
tients with no functional disability may be prescribed
non-pharmacological measures like exercise, educational
programs, and support services with close monitoring of
symptoms and quality of life. Once symptomatic treat-
ment is needed, the minimal dose of medication that re-
verses the disability should be used20. Levodopa is the
most effective antiparkinsonian agent12. As such, any
medication to increase its bioavailability and elimination
half-life (COMT inhibitors, MAO-B inhibitors, dopamine
reuptake inhibitors) would allow for less pulsatile dopa-
minergic stimulation. However, DA agonists are pre-
ferred as first-line agents11, particularly in patients with
a young onset of IPD. There are several reasons for such
an approach. Studies of non-ergot DA agonists alone in
early IPD showed successful treatment for several years21,
although these studies did not confirm non-inferiority to
levodopa. Moreover, long term head-to-head studies with
levodopa found a delay in time to onset of motor compli-
cations with DA agonists21, but at the expense of poorer
control of the symptoms of Parkinson’s disease and an
increase in psychiatric complications such as hallucina-
tions – which may be more important for patients and
caregivers than motor complications. DA agonists have
emerged as neuroprotective candidates, based on labora-
tory studies demonstrating their ability to protect dopa-
minergic and non-dopaminergic neurons in both in vitro
and in vivo models22 and clinical evidence based on
CALM-PD23 and REAL-PET24 studies. DA agonists in
clinical use also have longer half-lives than levodopa and
may have a longer duration of symptomatic effect. Addi-
tionally, levodopa has been shown to be neurotoxic in vi-
tro experiments although this neurotoxicity has not been
shown in vivo25 and are associated with sudden irresist-
ible sleep attacks26, excessive daytime sleepiness27, cogni-
tive impairment, and psychosis11. Conversely, fibrotic
pericardial and valvular heart disease and pulmonary
and retroperitoneal fibrosis have been reported with er-
got-derived DA agonists28–30, but not yet with non-ergot
DA agonists (ropinirole, pramipexole rotigotine). In young
patients, because of the longer treatment horizon, it is
preferable to initiate therapy with a non-ergot DA such
as rotigotine, pramipexole or ropinirole. Older patients
are usually commenced on levodopa therapy, because
they have a shorter treatment horizon, are more liable to
develop cognitive and psychiatric complications, and are
thought to be less likely to develop motor fluctuations
and dyskinesias with levodopa. Regardless of initial se-
lection of antiparkinsonian drug, L-dopa will be eventu-
ally used and will inevitably induce motor complications
during long-term treatment.
Further Directions of Development
Despite the number of agents approved for use in
IPD, neither a risk-free treatment with sustained benefit
nor has a preventive or curative agent been identified. In
addition, little is known regarding the benefit of any
therapeutic agent for a period of more than a few years.
A review of all trials so far found that the median fol-
low-up period per trial was two years; only 40% of trials
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in early PD went beyond 12 months. Therefore, there is a
need for new drug development in all aspects of PD ther-
apy. Development of a treatment with sustained thera-
peutic benefit over the decades of the disease would be
invaluable. The current concept of drug development in
IPD is directed to neuroprotection including slowing dis-
ease progression, motor symptoms and signs, complica-
tions induced by long-term L-dopa treatment, and non-
-motor symptoms and signs following IPD.
Neuroprotection strategy
Ideally, neuroprotective drugs should be considered as
pharmaco-prophylactic approach in the high risk popula-
tion, before clinically manifesting disease. However, nei-
ther such population nor agents have been identified so
far. Much effort has been directed to the development of
treatments that can stop or slow the progression of es-
tablished disease, but such an agent has not been identi-
fied unequivocally. There is no uniform opinion with re-
gard to the planning and conduct of such studies. Since
there is no biomarker of Parkinson’s disease progression,
primary endpoints are based on clinical measures of
parkinsonism. Because most people with Parkinson’s dis-
ease require symptomatic therapy within several months
to one year of diagnosis, such studies typically enroll only
those early in the course of disease who do not require
symptomatic therapy. New techniques are in develop-
ment for measuring cerebral dopamine uptake and dopa-
mine receptor density (SPECT and PET). The value of
diminished cerebral dopamine uptake and dopamine re-
ceptor density for measuring neuroprotective effect re-
mains to be established, as the predictive value of these
variables for the rate of progression in IPD has not been
validated. A method widely used in order to distinguish a
symptomatic effect from a neuroprotective effect is to
demonstrate that the effect is maintained in the active
treatment group relative to placebo after sufficient wash-
out of the study drug at the end of the treatment period.
A neuroprotective effect would be maintained whereas a
symptomatic effect would not be maintained. Care should
be taken to avoid confounding these effects with changes
in other symptomatic treatments and to avoid carry-over
effects due to unstable dopamine receptor sensitivity. A
typical development plan to investigate a drug proposed
to slow the progression of parkinsonism will include sev-
eral multicenter, double-blind, placebo controlled trials
investigating the safety and efficacy of one or several
doses of the drug. Patients included are recently diag-
nosed and not in need of symptomatic therapy. Prior ex-
posure to symptomatic antiparkinsonian therapy is pre-
cluded, or limited to a short time. Other agents proposed
to slow the progression of parkinsonism are also ex-
cluded. Primary endpoints trials designed to evaluate a
delay in progression of parkinsonism may include a need
to start dopaminergic therapy or a prespecified increase
in a standard measurement tool of parkinsonism. Sec-
ondary endpoints may include Unified Parkinson’s Dis-
ease Rating Scale (UPDRS) scores, Hoehn and Yahr
stage of illness, Schwab and England rating scale score,
and Clinical Global Impressions of Severity and Change,
as well as disease-specific Quality of Life measures (e.g.,
the PDQ-39, and PDQUALIF) or generic Quality of Life
measures (e.g., the EuroQol and SF-36) at specified time
points. Exploratory endpoints depend on the chemistry
of the intervention and can include non-motor elements
of Parkinson’s disease such as depression, cognition, hal-
lucinations, and dysautonomia. Rating scales for all of
these are derived from standard scales in the medical lit-
erature and have not been developed specifically for Par-
kinson’s disease in most instances. A new form of the
UPDRS has been recently developed31 as has a non-mo-
tor symptom assessment scale for Parkinson’s disease32,
but these have not yet been validated in clinical practice.
Because a neuroprotective drug would be expected to be
used for many years, or even for the entire duration of
disease, safety monitoring should allow detection of events
expected to occur at moderate frequency (0.5–5%). In
general, around 1200–1500 persons exposed in short-
and long-term studies should be adequate to detect dif-
ferences of around 2 to 3% across groups. To detect ad-
verse events occurring after prolonged use of the drug,
duration of monitoring should be at least 12 months for
some subjects. Depending on the specific agent, special
safety monitoring may be indicated.
Development of drugs for symptomatic
treatment of motor symptoms
While there are a number of agents with demon-
strated antiparkinsonian efficacy, none provides sustai-
ned symptomatic benefit throughout the course of this
disorder. The acute and chronic side effects of established
therapies are additional sources of concern. Trials of new
therapies should be designed to address these concerns,
with the goal of developing new drugs with more favor-
able efficacy and side effect profiles. A typical develop-
ment plan to investigate a drug proposed to provide
symptomatic improvement of parkinsonism would in-
clude several multicenter, double-blind, placebo-contro-
lled trials investigating the safety and efficacy of one or
several doses of the drug. Monotherapy trials, comparing
the study drug to placebo, will in most cases be limited to
early disease, enrolling »de novo« patients receiving symp-
tomatic therapy for the first time. Early monotherapy
studies restrict subjects to Hoehn-Yahr stage I–III (uni-
lateral or bilateral disease that may include mild balance
problems but no spontaneous falling) and sometimes to
Stage I–II only (no balance problems). The UPDRS is of-
ten used as the primary endpoint and may include the
Total score, part III only (examination of motor func-
tion), or part III + part II (patient’s motor activity of
daily living). Secondary and exploratory endpoints are
similar to those described in the neuroprotection strat-
egy. Because there is inevitable subjectivity in endpoint
determination, it is almost always desirable to require
that the primary outcome measure be determined by the
same rater, at a minimum for key time points (such as
enrollment and endpoint). It may be desirable to identify
specific raters within a center and/or to specify a re-
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quired level of expertise with the primary efficacy mea-
sure. A blocked randomization, either by investigator or
by center, is another approach to minimize the effect of
between-rater variability. To avoid »unblinding« and the
potential for a biased endpoint assessment, two raters
may be used – a »treating« investigator who evaluates
the patient at each visit and a »blinded« investigator who
determines performance on primary outcome measures
only at key visits and is otherwise prohibited from know-
ledge of the subject. Follow-up is often continued after
primary efficacy data have been obtained, whereas an ex-
tended follow-up can be especially valuable in monitor-
ing safety and to assess chronic efficacy. The analysis of
efficacy variables is based on the intention-to-treat strat-
egy. All statistical tests are two sided, and p-values <0.05
are considered statistically significant, though sometimes
adjusted p-values are used to account for multiple com-
parisons. In studies of advanced Parkinson’s disease, the
study drug will typically be given as adjunctive therapy
and compared to placebo given adjunctively, as it would
be unethical to withdraw existing therapies. Most com-
monly, the efficacy of the new agent when given in combi-
nation with a dopaminergic agent (usually L-dopa plus
decarboxylase inhibitor) is compared to the efficacy of
placebo combined with the same agent. Studies of drugs
that are added to current treatment in moderate Parkin-
son’s disease usually restrict patients to Hoehn-Yahr
stage II–IV and therefore include patients with poor bal-
ance. The addition of an adjunctive antiparkinsonian
agent can result not only in improvement of parkin-
sonism, but also in the new onset of dopaminergic side ef-
fects or the worsening of existing side effects, such as
dyskinesias or psychosis. Therefore, primary outcome
measures may include the UPDRS (total or Part III, or
Parts II + III for parkinsonism), the Abnormal Involun-
tary Movement Scale (AIMS), the Rush Dyskinesia Scale
in conjunction with a patient home diary for dyskinesia,
and the UPDRS part III/IV in conjunction with a patient
home diary for motor fluctuations. In addition, a global
measure such as a disease-specific quality of life measure
is essential, as it is otherwise impossible to interpret an
improvement in motor function coupled with a deteriora-
tion in side effects. An alternative design compares the
new drug to standard therapy. Design of such studies is
often difficult due to uncertainty regarding equivalence
of dosage. Some regulatory agencies may be less recep-
tive to comparison study designs. As for all development
plans, close contact with scientists in the regulatory
agencies is essential. Safety evaluations should take into
account the chronic use expected for most drugs in this
category. Therefore, safety monitoring should allow de-
tection of events expected to occur at moderate fre-
quency.
Development of drugs for the improvement
of already existing dyskinesia and motor
fluctuations
Dyskinesia and motor fluctuations are inevitable side
effects for most patients requiring L-dopa. These side ef-
fects are less frequently associated with DA agonists.
Studies focused to improve existing dyskinesias or motor
fluctuations are highly dependant on patient record and
require additional training of both investigators and pa-
tients. Patients have to be trained to recognize motor
fluctuation, make a difference between sensory and mo-
tor symptoms in various periods of L-dopa response, and
eventually properly record all those changes for trial pur-
poses. Dyskinesia are often intermittent, lasting from
several minutes to few hours, and very often patients are
not able to identify mild or even moderate dyskinesia.
Assessment of dyskinesia includes assessment of both its
severity and duration. Severity of dyskinesia is usually
rated with various scales like the AIMS or Rush dy-
skinesia scale, assessing all limbs, trunk, face, and neck,
but very often due to intermittent nature of movement
disorder, results can be inappropriate or misinterpreted.
In addition, dyskinesia can be activated by motor or men-
tal tasks, giving an incorrect impression of its severity.
For studies of motor fluctuations and dyskinesia, inclu-
sion criteria usually require baseline scores for the target
problem sufficiently severe enough to allow for deteriora-
tion during the trial. For dyskinesias, a minimal baseline
severity score on the AIMS (variably 7–10) is often used,
together with minimal daily duration of dyskinesia be-
tween 26–50% based on diaries or UPDRS. For motor
fluctuation, inclusion often requires a minimal 2 to 3
hours daily of off time recorded in the patient’s diary be-
tween screening and baseline visits. These criteria are in-
troduced to avoid »floor effects«. There is no ideal model
for dyskinesia severity assessment, but one recently pub-
lished one seems very useful. Patients were observed for
several hours with video recording, and blind assessment
of dyskinesia severity by two independent neurologists
was performed33. The primary endpoint is typically a
dyskinesia and motor fluctuation assessment, usually a
time spent in various motor stages (»on without dy-
skinesia«, »on with troublesome dyskinesia«, and »off«
stage). Currently there are no medications labeled for
the treatment of dyskinesia, although there are few ran-
domized controlled trials (RCT) providing evidence that
clozapine and/or amantadine might be useful as a short-
-term (i.e., a few months) treatment.
Development of drugs which will delay the
development of dyskinesias or motor fluctuations
Special types of trials are those assessing the first
time occurrence of dyskinesia and motor fluctuation in
patients with early or advanced IPD. These studies are
very long (up to 5 years), and randomized double blind
placebo controlled parallel design is the standard. Stu-
dies usually involve the enrollment of several hundred
patients, and therefore multiple centers are usually in-
volved. A final visit shortly after drug-exposure cessation
is standard for safety monitoring and allows the detec-
tion of withdrawal effects on primary and secondary out-
comes. These studies enroll patients who at baseline are
in need of symptomatic antiparkinsonian therapy. IPD
patients must be newly in need of symptomatic anti-
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parkinsonian therapy, typically Hoehn and Yahr Stage
I–III. They should have no prior exposure or very mini-
mal prior exposure to dopaminergic drugs and should not
have motor fluctuations or dyskinesias at baseline. The
study randomizes patients to standard dopaminergic the-
rapy, usually levodopa, or the new study drug. Because
these studies are long in duration, some protocols permit
the addition of levodopa in both groups if inadequate effi-
cacy of treatment is encountered in the midst of the
study period. Primary endpoints typically include time to
development of these complications and a percentage of
the population at given time points that has the compli-
cation. Secondary endpoints include measures of park-
insonian impairment, such as UPDRS scores, Clinical
Global Impressions of Severity and Change, and Quality
of Life measures such as the PDQ-39 and PDQUALIF.
Secondary endpoints can also include a neuroimaging
outcome measuring the uptake of ligands specific to the
dopamine system, such as [123I]b-CIT (2b-carbomethoxy-
-3b –[4-iodophenvl]) and single photon positron emission
tomography (SPECT) or [18F]-dopa and positron emis-
sion tomography (PET) scanning indices. The analyses
are based on the intention-to-treat strategy. All statisti-
cal tests are two-sided, and p-values <0.05 are consid-
ered statistically significant, though sometimes adjusted
p-values are used to account for multiple comparisons.
The primary analysis for studies involving delay in the
development of motor complications uses a survival ap-
proach and calculates the cumulative probability of
reaching each endpoint. Differences in outcome are ex-
pressed as hazard functions, usually with the Kaplan-
-Meier estimate, which can be displayed graphically. It is
important to censor individuals who either drop out or
have limited follow-up. Hypothesis testing between groups
can use the log rank test or Cox’s proportional hazard re-
gression modeling, which allows adjustment for multiple
covariates.
Development of drugs for non-motor
symptoms of Parkinson’s disease
Outside of the primary motor elements of IPD (par-
kinsonism and motor complications), PD patients experi-
ence a number of other disabilities, including sleep disor-
der, cognitive impairment, depression, apathy, hallucina-
tions, dysautonomia, pain, bladder, bowel and sexual dys-
function, fatigue, and many others. Most of these symp-
toms worsen during the L-dopa »wearing-off« and »off«
phases and have a dramatic effect on the lives of both PD
patients and caregivers34. Non-motor symptoms of IPD
are not well recognized in clinical practice, either in pri-
mary and secondary care. Depression, anxiety, fatigue,
and sleep disturbance are among the most troubling
symptoms for IPD patients, but during routine consulta-
tions, these symptoms are not identified by neurologists
in over 50% of consultations. Sleep disturbance in partic-
ular is not recognized in over 40% of patients35. Interest
is growing in the evidence based treatment of non-motor
symptoms, but in part, its success will depend not just on
the identification but also on the quantification of the ef-
fects of treatment on patients’ baseline disability. Drugs
that are useful in treating these symptoms in other medi-
cal contexts can be tested through randomized dou-
ble-blind, placebo-controlled trials of IPD subjects with
the target problem and appropriately designed measure-
ment tools adapted from other medical fields. However it
seems that symptom-specific instruments are still not
validated and may not be relevant to people with IPD36.
Regardless of instruments used, the analysis of efficacy
variables is based on the intention-to-treat strategy, as
previously mentioned.
Conclusion
Treatment aims in PD include the provision of symp-
tomatic relief, reduction of functional disability, halting
or slowing of the neurodegenerative process, and the pre-
vention of long-term complications by proper initiation
of therapy. At present, pharmacotherapeutic strategies
allow the amelioration of motor symptoms of IPD only,
whereas non-motor manifestations are not helped by do-
pamine replacement strategies. In addition, levodopa-in-
duced fluctuation and dyskinesia are still challenging,
particularly in long-term treatment. Despite advances in
pharmacotherapy that have improved quality of life for
these patients, the mortality rate remains largely un-
changed. Recent studies have found that patients with
Parkinson’s disease have a two-fold to five-fold higher
mortality rate than control subjects37–38. This is within
the range of Hoehn and Yahr’s observations from 196739.
Sustained interest in IPD will hopefully allow increased
funding of research to develop new and better treat-
ments.
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PARKINSONOVA BOLEST – IZAZOVI U RAZVOJU NOVIH LIJEKOVA
S A @ E T A K
Idiopatska Parkinsonova bolest je nakon Alzheimerove bolesti, naj~e{}a neurodegenerativna bolest. Ciljevi lije~enja
uklju~uju ubla`avanje simptoma bolesti, smanjenje funkcionalne nesposobnosti, zaustavljanje ili usporenje neurodege-
nerativnog procesa i prevenciju dugotrajnih komplikacija inicijacijom odgovaraju}e terapije. Sada{nje farmakoterapij-
ske strategije dovode samo do olak{avanja motornih simptoma bolesti, dok nadomjesna dopaminska terapija nije u~in-
kovita u lije~enju ne-motornih manifestacija bolesti. Osim toga, levodopom inducirane fluktuacije i diskinezije pred-
stavlju izazov za razvoj novih lijekova i to osobito u dugotrajnom lije~enju. Unato~ napretku u farmakoterapiji idiopatske
Parkinsonove bolesti koja je pobolj{ala kvalitetu `ivota tih bolesnika, mortalitet je ostao i dalje nepromijenjen. Podr-
`avanje zanimanja za idiopatsku Parkinsonovu bolesti pridonijet }e razvoju nove i u~inkovitije terapije.
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